Express Scripts’ Payer Clients On Board With Indication-Based Pricing, Exec Says
This article was originally published in The Pink Sheet Daily
PBM provides an update on its indication-based pricing project for oncology drugs, claiming it has found a way around the Medicaid “best price” dilemma.
You may also be interested in...
Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.
In a marked departure from previous years, budget proposal offers few specifics on cost reductions, but the $135bn savings estimate is a tacit endorsement of the Grassley-Wyden bill in the Senate.
But cost sharing for non-preferred specialty drugs cannot exceed the current 25%-33% coinsurance currently allowed for the specialty tier, the Centers for Medicare and Medicaid Services says in a proposed rule.